With one of the relatively newer but important anti-diabetic drugs, Vildagliptin manufactured by Novartis, losing patent protection in December, dozens of companies are readying plans to launch the generic version to get a slice of the action in the growing Rs 13,000-crore diabetes therapy. The cost of therapy is expected to reduce by over 50%.
from The Times of India https://ift.tt/2YiRItr
No comments:
Post a Comment